ARAY - Accuray Incorporated
NASDAQ
->
Healthcare
->
Medical Devices
Sunnyvale,
United States
Type: Equity
ARAY price evolution
ARAY
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $62.15 | $74.49 | ||
| Short term investments | ||||
| Net receivables | $91.79 | $92 | $73.15 | $77.4 |
| Inventory | $154.88 | $138.32 | $159.57 | $155.23 |
| Total current assets | $329.54 | $323.24 | $313.91 | $331.17 |
| Long term investments | $13.59 | $14.54 | ||
| Property, plant & equipment | $58.48 | $58.55 | $54.51 | $49.01 |
| Goodwill & intangible assets | $57.75 | $57.89 | ||
| Total noncurrent assets | $148.62 | $145.18 | ||
| Total investments | $13.59 | $14.54 | ||
| Total assets | $473.08 | $468.63 | $462.53 | $476.35 |
| Current liabilities | ||||
| Accounts payable | $49.81 | $50.02 | $44.43 | $39.18 |
| Deferred revenue | $97.36 | $102.22 | ||
| Short long term debt | $12.53 | $12.45 | ||
| Total current liabilities | $201.81 | $195.27 | $198.39 | $209.31 |
| Long term debt | $162.47 | $164.4 | $194.46 | $189.78 |
| Total noncurrent liabilities | $223.06 | $219.39 | ||
| Total debt | $206.99 | $202.22 | ||
| Total liabilities | $427.86 | $423.54 | $421.45 | $428.7 |
| Shareholders' equity | ||||
| Retained earnings | -$521.63 | -$517.68 | -$521.07 | -$514.73 |
| Other shareholder equity | -$2.48 | -$4.22 | -$1.91 | $1.06 |
| Total shareholder equity | $41.08 | $47.65 | ||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $91.2 | $90.15 | $118.2 | |
| Short term investments | ||||
| Net receivables | $92 | $74.78 | $94.44 | $85.36 |
| Inventory | $138.32 | $145.15 | $142.25 | $125.93 |
| Total current assets | $323.24 | $338.03 | $350.89 | $352.77 |
| Long term investments | $15.13 | $13.88 | $15.94 | |
| Property, plant & equipment | $58.55 | $46.78 | $29.48 | $34.85 |
| Goodwill & intangible assets | $57.89 | $58.09 | $58.4 | |
| Total noncurrent assets | $141.18 | $121.96 | $127.33 | |
| Total investments | $15.13 | $13.88 | $15.94 | |
| Total assets | $468.63 | $479.21 | $472.85 | $480.1 |
| Current liabilities | ||||
| Accounts payable | $50.02 | $33.74 | $31.34 | $19.47 |
| Deferred revenue | $99.26 | $100.07 | $105.34 | |
| Short long term debt | $9.87 | $17.13 | $11.96 | |
| Total current liabilities | $195.27 | $198.64 | $208.86 | $192.36 |
| Long term debt | $164.4 | $171.56 | $182.36 | $187.45 |
| Total noncurrent liabilities | $226.92 | $210.8 | $218.9 | |
| Total debt | $205.04 | $199.49 | $199.41 | |
| Total liabilities | $423.54 | $425.56 | $419.66 | $411.26 |
| Shareholders' equity | ||||
| Retained earnings | -$517.68 | -$502.14 | -$492.52 | -$488.02 |
| Other shareholder equity | -$4.22 | $0.42 | $2.41 | $2.09 |
| Total shareholder equity | $53.66 | $53.19 | $68.84 | |
| (in millions $) | 1 May 2025 | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $134.29 | |||
| Cost of revenue | ||||
| Gross Profit | $38.45 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $31.63 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.47 | |||
| Interest expense | $0.81 | |||
| Net income | ||||
| Net income | $3.39 | |||
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $446.55 | $429.91 | $396.29 | |
| Cost of revenue | $269.95 | $236.78 | ||
| Gross Profit | $142.92 | $159.96 | $159.51 | |
| Operating activities | ||||
| Research & development | $57.75 | $52.73 | ||
| Selling, general & administrative | $94.06 | $84.54 | ||
| Total operating expenses | $142.42 | $151.81 | $137.27 | |
| Operating income | $8.15 | $22.23 | ||
| Income from continuing operations | ||||
| EBIT | -$2 | -$4.56 | ||
| Income tax expense | $3.73 | $3.35 | $1.75 | |
| Interest expense | $1.84 | |||
| Net income | ||||
| Net income | -$15.54 | -$5.35 | -$6.31 | |
| Income (for common shares) | -$5.35 | -$6.31 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$6.34 | -$9.62 | ||
| Operating activities | ||||
| Depreciation | $1.6 | $1.55 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.73 | $2.31 | ||
| Total cash flows from operations | -$8.1 | -$5.09 | ||
| Investing activities | ||||
| Capital expenditures | -$0.8 | -$1.25 | ||
| Investments | ||||
| Total cash flows from investing | -$1.12 | -$3.6 | -$0.8 | -$1.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.36 | |||
| Net borrowings | -$1.5 | -$1.5 | ||
| Total cash flows from financing | -$2.17 | -$3.95 | -$1.5 | -$0.26 |
| Effect of exchange rate | $1.33 | -$1.35 | -$1.94 | $2.4 |
| Change in cash and equivalents | -$9.26 | -$20.81 | -$12.34 | -$4.2 |
| (in millions $) | 30 Jul 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$9.28 | -$5.35 | -$6.31 | |
| Operating activities | ||||
| Depreciation | $4.53 | $5.51 | $6.39 | |
| Business acquisitions & disposals | -$0.08 | |||
| Stock-based compensation | $10.05 | $10.6 | $9.33 | |
| Total cash flows from operations | $15.54 | -$2.4 | $38.51 | |
| Investing activities | ||||
| Capital expenditures | -$12.61 | -$4.72 | -$2.32 | |
| Investments | ||||
| Total cash flows from investing | -$3.6 | -$12.68 | -$4.72 | -$2.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.2 | $3.89 | -$11.05 | |
| Net borrowings | -$4.11 | -$19 | -$17.41 | |
| Total cash flows from financing | -$3.95 | -$2.11 | -$15.37 | -$28.8 |
| Effect of exchange rate | -$1.35 | $0.3 | -$5.56 | $0.98 |
| Change in cash and equivalents | -$20.81 | $1.05 | -$28.05 | $8.29 |
News
Fundamentals
| Market cap | $185.81M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 100.44M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.63 |
| Quick ratio | 0.87 |